- Home
- ADVM vs IMA Comparison
ADVM vs IMA Comparison
Compare ADVM & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- IMA
- Stock Information
- Founded
- ADVM 2006
- IMA 2019
- Country
- ADVM United States
- IMA United States
- Employees
- ADVM N/A
- IMA N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADVM Health Care
- IMA Health Care
- Exchange
- ADVM Nasdaq
- IMA Nasdaq
- Market Cap
- ADVM 94.6M
- IMA 92.2M
- IPO Year
- ADVM 2014
- IMA N/A
- Fundamental
- Price
- ADVM $4.31
- IMA $8.22
- Analyst Decision
- ADVM Buy
- IMA Buy
- Analyst Count
- ADVM 5
- IMA 1
- Target Price
- ADVM $16.60
- IMA $30.00
- AVG Volume (30 Days)
- ADVM 1.0M
- IMA 66.5K
- Earning Date
- ADVM 11-07-2025
- IMA 11-13-2025
- Dividend Yield
- ADVM N/A
- IMA N/A
- EPS Growth
- ADVM N/A
- IMA N/A
- EPS
- ADVM N/A
- IMA N/A
- Revenue
- ADVM $1,000,000.00
- IMA $4,300,000.00
- Revenue This Year
- ADVM $1,191.10
- IMA N/A
- Revenue Next Year
- ADVM N/A
- IMA N/A
- P/E Ratio
- ADVM N/A
- IMA N/A
- Revenue Growth
- ADVM N/A
- IMA N/A
- 52 Week Low
- ADVM $1.78
- IMA $7.24
- 52 Week High
- ADVM $8.18
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- ADVM 50.55
- IMA N/A
- Support Level
- ADVM $4.18
- IMA N/A
- Resistance Level
- ADVM $4.37
- IMA N/A
- Average True Range (ATR)
- ADVM 0.20
- IMA 0.00
- MACD
- ADVM -0.03
- IMA 0.00
- Stochastic Oscillator
- ADVM 51.58
- IMA 0.00
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.